| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three and six months ended May 31, 2024 and 2023:
|
|
|
|
|
|
|
|
|
|
|
For the three months ended May 31, |
|
|
|
2024 |
|
|
2023 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
7,965,500 |
|
|
$ |
7,581,697 |
|
PrepaCyte CB |
|
|
35,834 |
|
|
|
27,177 |
|
Public cord blood banking |
|
|
41,477 |
|
|
|
163,816 |
|
Total net revenue |
|
$ |
8,042,811 |
|
|
$ |
7,772,690 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,830,453 |
|
|
$ |
1,802,882 |
|
PrepaCyte CB |
|
|
10,380 |
|
|
|
9,328 |
|
Public cord blood banking |
|
|
183,917 |
|
|
|
330,976 |
|
Total cost of sales |
|
$ |
2,024,750 |
|
|
$ |
2,143,186 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,515,506 |
|
|
$ |
1,184,513 |
|
PrepaCyte CB |
|
|
18,510 |
|
|
|
10,905 |
|
Public cord blood banking |
|
|
(142,498 |
) |
|
|
(167,520 |
) |
Total operating profit |
|
$ |
1,391,518 |
|
|
$ |
1,027,898 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
52,796 |
|
|
$ |
273,776 |
|
PrepaCyte CB |
|
|
6,944 |
|
|
|
6,944 |
|
Public cord blood banking |
|
|
58 |
|
|
|
360 |
|
Total depreciation and amortization |
|
$ |
59,798 |
|
|
$ |
281,080 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
329,273 |
|
|
$ |
469,952 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
329,273 |
|
|
$ |
469,952 |
|
|
|
|
|
|
|
|
|
|
For the six months ended May 31, |
|
|
|
2024 |
|
|
2023 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
15,771,022 |
|
|
$ |
15,143,215 |
|
PrepaCyte CB |
|
|
38,834 |
|
|
|
59,377 |
|
Public cord blood banking |
|
|
85,190 |
|
|
|
394,513 |
|
Total net revenue |
|
$ |
15,895,046 |
|
|
$ |
15,597,105 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
3,715,019 |
|
|
$ |
3,490,132 |
|
PrepaCyte CB |
|
|
35,863 |
|
|
|
26,450 |
|
Public cord blood banking |
|
|
434,336 |
|
|
|
693,968 |
|
Total cost of sales |
|
$ |
4,185,218 |
|
|
$ |
4,210,550 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
2,573,225 |
|
|
$ |
2,992,206 |
|
PrepaCyte CB |
|
|
(10,918 |
) |
|
|
19,038 |
|
Public cord blood banking |
|
|
(349,566 |
) |
|
|
(300,175 |
) |
Total operating profit |
|
$ |
2,212,741 |
|
|
$ |
2,711,069 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
78,675 |
|
|
$ |
547,315 |
|
PrepaCyte CB |
|
|
13,889 |
|
|
|
13,889 |
|
Public cord blood banking |
|
|
420 |
|
|
|
720 |
|
Total depreciation and amortization |
|
$ |
92,984 |
|
|
$ |
561,924 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
585,732 |
|
|
$ |
936,183 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
585,732 |
|
|
$ |
936,183 |
|
The following table shows the assets by segment as of May 31, 2024 and November 30, 2023:
|
|
|
|
|
|
|
|
|
|
|
As of |
|
|
As of |
|
|
|
May 31, 2024 |
|
|
November 30, 2023 |
|
Assets: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell
service |
|
$ |
56,915,873 |
|
|
$ |
55,471,149 |
|
PrepaCyte CB |
|
|
111,921 |
|
|
|
148,040 |
|
Public cord blood banking |
|
|
5,538,802 |
|
|
|
5,601,581 |
|
Total assets |
|
$ |
62,566,596 |
|
|
$ |
61,220,770 |
|
|